Sales of over 500 million
“The results of the studies and our solid financial performance, at the same time as we have built a platform for future growth and signed important distribution agreements, demonstrates the strength of our business model, our employees and our products.”
3 May 2017, 8.00 Interim management statement, 1 January – 31 March 2017
3 May 2017, 17:00 Annual General Meeting, 5:00 p.m. at Lundqvist & Lindqvist Conference, Klarabergsviadukten 90, in Stockholm.
Right to participate
In order to participate in the Annual General Meeting (AGM), shareholders must be recorded in the register of shareholders maintained by Euroclear Sweden AB no later than Wednesday 26 April 2017 and must provide notice of participation to the company no later than Thursday 27 April 2017. Notification can be made by mail to BioGaia AB (publ), Box 3242, SE-103 64 Stockholm, Sweden, by telephone +46 (0)8-555 293 00, by fax +46 (0)8-555 293 01 or by e-mail to email@example.com. The notification should include the shareholder’s name, personal or corporate identity number, address, telephone number, registered shareholding and the names of any proxies or assistants.
In order to participate in the AGM, shareholders whose shares are registered in the name of a trustee must temporarily re-register the shares in their own name. Such registration, which may be temporary, must be completed Wednesday 26 April 2017.
Form of proxy
Shareholders who are represented by a proxy must submit a dated form of proxy. If the form of proxy is submitted by a legal entity, a copy of the certificate of registration or other proof of authorisation for the legal entity must be attached. A form of proxy can be downloaded from the company’s website www.biogaia.com. An original form of proxy and, where appropriate, a certificate of registration or other proof of authorisation should be received by the company at the above address no later than Thursday 27 April 2017.
18 August 2017 Interim report, 1 January – 30 June 2017
25 October 2017 Interim management statement, 1 January – 30 September 2017